Melanie de Almeida

Melanie joined the Forbion investment team in September 2022 as an intern after receiving her Ph.D in Oncology from the University of Vienna. During her graduate studies, she developed new approaches to investigate aberrant transcriptional programs in cancer cells by utilizing genome-wide CRISPR/Cas9 screens. Melanie has published in several high-impact journals including Nature and received an award from MIT in recognition of her Ph.D work. Prior to her Ph.D, Melanie gained diverse insights into the life science industry through internships with Novo Nordisk and Labiotech.eu.

She holds a MSc. in Human Biology from the University of Copenhagen and a BSc. in Molecular Biotechnology from RWTH Aachen University.